# Lactobacillus rhamnosus GG

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/lactobacillus-rhamnosus-gg
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** LGG, Lacticaseibacillus rhamnosus GG, Lactobacillus rhamnosus strain GG, ATCC 53103, DSM 33156, Lactobacillus GG, L. rhamnosus GG

## Overview

Lactobacillus rhamnosus GG (LGG) is a gram-positive lactic acid bacterium that colonizes the intestinal epithelium via surface-layer proteins (SpaCBA pili) and lipoteichoic acid, modulating immune signaling and reinforcing the mucosal barrier. Its primary mechanisms include stimulating secretory IgA production, competitively excluding pathogens, and upregulating tight junction proteins such as occludin and claudin-3 to reduce [intestinal permeability](/ingredients/condition/gut-health).

## Health Benefits

• Reduces diarrhea duration by 24 hours and decreases stool frequency in children with acute gastroenteritis, especially rotavirus (strong evidence from meta-analysis of 19 RCTs, PMID: 31543689)
• Decreases necrotizing enterocolitis risk by 50% in preterm infants (moderate evidence from meta-analysis of 5 RCTs, n=851)
• Lowers respiratory infection risk by 13% (strong evidence from meta-analysis of 69 trials, PMID: 40702885)
• Reduces overall gastrointestinal symptoms by 12% across multiple conditions (strong evidence from meta-analysis, PMID: 40702885)
• Decreases acute diarrhea risk by 36% in children and adults (strong evidence from meta-analysis of 24 trials, PMID: 40702885)

## Mechanism of Action

LGG adheres to intestinal epithelial cells via SpaCBA pilus proteins, activating Toll-like receptor 2 (TLR-2) signaling pathways that stimulate NF-κB-mediated [anti-inflammatory](/ingredients/condition/inflammation) cytokine modulation, increasing IL-10 while suppressing TNF-α and IL-6. It produces lactic acid and short-chain fatty acids that lower luminal pH, inhibiting pathogen growth and promoting colonocyte [energy metabolism](/ingredients/condition/energy) via butyrate uptake. LGG also upregulates expression of tight junction proteins occludin, claudin-3, and ZO-1, directly reducing epithelial permeability and strengthening the mucosal barrier against microbial translocation.

## Clinical Summary

A meta-analysis of 19 RCTs (PMID: 31543689) demonstrated that LGG supplementation reduces diarrhea duration by approximately 24 hours and significantly decreases stool frequency in children with acute gastroenteritis, with the strongest effect observed against rotavirus. A separate meta-analysis in preterm infants found a roughly 50% reduction in necrotizing enterocolitis (NEC) incidence, though evidence quality is rated moderate due to heterogeneity across neonatal populations. Evidence for LGG in antibiotic-associated diarrhea prevention is strong, with multiple RCTs showing a relative risk reduction of 40–60% when LGG is administered concurrently with antibiotic therapy. Evidence for IBS symptom relief and atopic disease prevention is emerging but inconsistent, warranting cautious interpretation.

## Nutritional Profile

Lactobacillus rhamnosus GG (LGG) is a live microbial preparation, not a conventional food ingredient, so macronutrient contribution is negligible at typical therapeutic doses (1×10⁸ to 1×10¹¹ CFU/day). Key bioactive components include: (1) Surface-layer proteins (Slp) and pili structures (SpaC pilin tip protein) that mediate host epithelial adhesion and immune signaling; (2) Lipoteichoic acid (LTA) in cell wall, a toll-like receptor 2 (TLR-2) ligand involved in [immunomodulat](/ingredients/condition/immune-support)ion; (3) Secreted proteins including p40 and p75 (serine proteinases, ~40 kDa and ~75 kDa respectively) that activate epidermal growth factor receptor (EGFR) and promote intestinal epithelial cell survival; (4) Exopolysaccharides (EPS) produced at approximately 100–300 mg/L in culture, contributing to biofilm formation and gut mucosa interaction; (5) Short-chain fatty acids (SCFAs) produced via fermentation, primarily lactic acid (D- and L-isomers, ~10–20 mmol/L in culture supernatant) and acetic acid (~2–5 mmol/L), with trace butyrate; (6) Bacteriocin-like inhibitory substances (BLIS) with antimicrobial activity against pathogens including Clostridium difficile and Salmonella spp.; (7) B-vitamins synthesized endogenously including folate (B9, ~15–50 ng/mL culture supernatant) and riboflavin (B2, trace quantities). When delivered in fermented dairy carriers (e.g., yogurt), additional nutrients include protein (~3.5 g/100g), calcium (~120 mg/100g), and lactose (~4.5 g/100g), though these are carrier-derived. Bioavailability note: LGG survives gastric transit at pH ≥2.5 with >40% viability recovery in the ileum, significantly higher than non-encapsulated strains; microencapsulation in alginate or milk fat matrices increases colonic delivery efficiency by approximately 20–30%. Viable cell count degrades rapidly above 25°C and below pH 4.0 in formulations.

## Dosage & Preparation

Clinically studied doses range from 10^10 CFU twice daily for 5 days in pediatric acute gastroenteritis to ≥10^10 CFU/day for optimal diarrhea reduction. Available in powder or suspension forms, standardized to CFU counts. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

LGG is generally recognized as safe (GRAS status, FDA) in healthy individuals at doses of 10⁹–10¹⁰ CFU per day, with the most common adverse effects being mild bloating and flatulence during the first week of use. Immunocompromised individuals, patients with central venous catheters, or those with short bowel syndrome carry a rare but documented risk of LGG bacteremia and septicemia, with over 200 case reports published in the literature. LGG should be taken at least 2 hours apart from antibiotic medications to preserve viable colony counts, as concurrent administration reduces efficacy. No established contraindications exist for pregnancy or lactation, and LGG is widely used in neonatal and pediatric clinical settings, though consultation with a healthcare provider is recommended for preterm infants.

## Scientific Research

A 2024 meta-analysis of 69 trials (PMID: 40702885) demonstrated LGG's efficacy in reducing diarrhea risk (RR 0.64) and respiratory infections (RR 0.87). Another meta-analysis of 19 RCTs (PMID: 31543689) showed high-dose LGG (≥10^10 CFU/day) reduced diarrhea duration by 24 hours, while a large multicenter RCT protocol (n=970 children, NCT01773967; PMID: 28947466) tested LGG for moderate-to-severe acute gastroenteritis.

## Historical & Cultural Context

LGG has no traditional medicine history as it was only isolated in 1983 from human intestinal microbiota and developed specifically for clinical [probiotic](/ingredients/condition/gut-health) applications. The strain has accumulated 30 years of randomized controlled trial evidence rather than traditional use.

## Synergistic Combinations

Other Lactobacillus strains, Bifidobacterium species, Saccharomyces boulardii, [Prebiotic](/ingredients/condition/gut-health) fibers, Zinc

## Frequently Asked Questions

### How long does Lactobacillus rhamnosus GG take to work for diarrhea?

Clinical trial data show LGG reduces diarrhea duration by approximately 24 hours compared to placebo, with measurable decreases in stool frequency observed within 48–72 hours of initiating supplementation at doses of 10¹⁰ CFU twice daily. The effect is most pronounced in rotavirus-associated gastroenteritis in children under five, where LGG shortens illness by up to 1.5 days based on pooled meta-analysis data.

### What is the clinically effective dose of Lactobacillus rhamnosus GG?

Most clinical trials supporting LGG's benefits used doses ranging from 10⁹ to 10¹⁰ colony-forming units (CFU) per day, typically divided into one or two daily doses. For antibiotic-associated diarrhea prevention, 1–2 × 10¹⁰ CFU per day initiated at the start of antibiotic therapy is the most studied protocol, while pediatric gastroenteritis trials commonly used 10¹⁰ CFU twice daily for five days.

### Is Lactobacillus rhamnosus GG safe for infants and newborns?

LGG is widely used in neonatal research and has demonstrated a 50% reduction in necrotizing enterocolitis risk in preterm infants in meta-analyses; however, rare cases of LGG bacteremia have been reported in extremely low-birth-weight neonates and immunocompromised infants. Healthy full-term infants are generally considered low risk, but administration in NICU settings or for infants with central lines should occur only under direct medical supervision.

### Can Lactobacillus rhamnosus GG be taken with antibiotics?

Yes, LGG is specifically recommended for concurrent antibiotic use to prevent antibiotic-associated diarrhea, with RCTs showing a 40–60% relative risk reduction in AAD incidence. To preserve viable CFU counts, LGG should be administered at least 2 hours after each antibiotic dose, as many antibiotics directly inhibit or kill LGG strains when co-administered simultaneously.

### Does Lactobacillus rhamnosus GG help with IBS symptoms?

Evidence for LGG in irritable bowel syndrome is mixed; some RCTs report modest reductions in abdominal pain frequency in children with IBS-type symptoms, with one study showing a 50% responder rate versus 25% for placebo, but adult IBS trials have produced inconsistent results. The proposed mechanism involves TLR-2-mediated reduction of visceral hypersensitivity and restoration of tight junction integrity, but current evidence does not support LGG as a first-line IBS treatment in adults.

### Is Lactobacillus rhamnosus GG effective for preventing respiratory infections?

Yes, clinical evidence shows Lactobacillus rhamnosus GG reduces respiratory infection risk by approximately 13% based on meta-analysis of multiple randomized controlled trials. This effect is most pronounced in children and may be linked to the strain's ability to enhance intestinal barrier function and systemic immune response. However, the absolute risk reduction is modest, making it a supportive rather than primary prevention strategy.

### Can Lactobacillus rhamnosus GG prevent necrotizing enterocolitis in premature infants?

Moderate clinical evidence suggests Lactobacillus rhamnosus GG may reduce necrotizing enterocolitis risk by approximately 50% in preterm infants, based on meta-analysis of 5 randomized controlled trials involving 851 infants. This is a significant finding given the serious morbidity of necrotizing enterocolitis in neonatal intensive care units. However, further large-scale trials are recommended before widespread clinical implementation in all preterm populations.

### Which conditions has Lactobacillus rhamnosus GG been most studied for in clinical trials?

Lactobacillus rhamnosus GG has the strongest clinical evidence for acute gastroenteritis in children (particularly rotavirus diarrhea), with 19 randomized controlled trials demonstrating a 24-hour reduction in diarrhea duration, as well as studies on necrotizing enterocolitis prevention in preterm infants and respiratory infection reduction. It also shows clinical benefit for irritable bowel syndrome symptoms and traveler's diarrhea. While some evidence exists for other conditions, these four areas have the most robust research support.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*